Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Master Framework and Pragmatic Clinical Trial for Relapse or Refractory Acute Myeloid Leukemia

Project description

Clinical trial for relapsed or refractory acute myeloid leukaemia

Current strategies for developing treatments for patients with relapsed or refractory acute myeloid leukaemia (R/R AML) rely on small research groups. However, studying large datasets and conducting trials across diverse patient populations is resource-intensive, time-consuming, and requires extensive monitoring. In this context, the EU-funded IMPACT-AML project aims to address these challenges by establishing a prospective randomised clinical trial (PRCT) that unites research groups across Europe. This collaborative approach will enable the study of multiple patient groups across various locations, generating comprehensive data to advance new treatments and solutions for R/R AML.

Objective

In IMPACT-AML, a multidisciplinar R/R AML represents a model of high-impact disease, in which no standard of care exists, and where we have an urgent need for new evidence on possible therapies; AML offers the setting in which methodological innovation will combine powerful instruments of clinical trials with personalized medicine through academic efforts. Hereby, we propose to create an inclusive master framework for relapsed or refractory acute myeloid leukemia (STREAM) to include patients with R/R AML across Europe proficiently acquire an unselected population for clinical trials and monitor outcomes including neglected cohorts. Thereafter we will conduct a prospective randomized pragmatic clinical trial (RPCT) that will compare the classical “high intensity” rescue chemotherapy with biology-driven, “low intensity” rescue to obtain “real world” data on the benefit of one of the two different strategies in term of survival also considering patients and caregivers preferences, patient-reported outcomes (PRO), accessibility, affordability, and social cost.
RPCT will aim to evaluate the effectiveness of real-world clinical alternatives in routine care. In addition to retaining the high internal validity of traditional randomized trials, it will maximize external validity, i. e. generalizability of results to many settings. In this context, the inclusion of an RPCT in the master framework will allow a dynamic inclusion and the collection of the excluded population as an instrument to predict the real-life applicability of clinical trial results. We will offer Europe results from an ambitious project, that will go beyond the state of the art in R/R AML demonstrating the superiority of a strategy in a first-of-his-kind clinical trial, providing strong data that will be delivered to national health care providers, policymakers, and health authorities data on optimized and affordable treatment for R/R AML and promoting the implementation of the selected better option. This action is part of the Cancer Mission cluster of projects on ‘Diagnosis and treatment’.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-RIA - HORIZON Research and Innovation Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MISS-2022-CANCER-01

See all projects funded under this call

Coordinator

ISTITUTO ROMAGNOLO PER LO STUDIO DEI TUMORI DINO AMADORI - IRST SRL
Net EU contribution
€ 1 511 970,75
Address
VIA MARONCELLI 40
47014 Meldola
Italy
Region
Nord-Est Emilia-Romagna Forlì-Cesena
Activity type
Research Organisations
Links
Total cost
€ 1 511 970,75

Participants (19)